Long-term “real-life” safety of omalizumab in patients with severe uncontrolled asthma: A nine-year study-Reference-Cited by-同舟云学术

Long-term “real-life” safety of omalizumab in patients with severe uncontrolled asthma: A nine-year study

Published:2017-09 Issue: Volume:130 Page:55-60
ISSN:0954-6111
Container-title:Respiratory Medicine
language:en
Short-container-title:Respiratory Medicine

Author:

Di Bona Danilo^ORCID,Fiorino Irene,Taurino Marialuisa,Frisenda Flavia,Minenna Elena,Pasculli Carlo,Kourtis Georgios,Rucco Anna Simona,Nico Andrea,Albanesi Marcello,Giliberti Lucia,D'Elia Luciana,Caiaffa Maria Filomena,Macchia Luigi

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine

Reference30 articles.

1. Omalizumab for asthma in adults and children;Normansell;Cochrane Database Syst. Rev.,2014

2. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): innovate;Humbert;Allergy,2005

3. Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma;Lanier;J. Allergy Clin. Immunol.,2009

4. Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial;Hanania;Ann. Intern. Med.,2011

5. Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children;Busse;N. Engl. J. Med.,2011

Cited by 71 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Type 2 severe asthma: pathophysiology and treatment with biologics;Expert Review of Respiratory Medicine;2024-07-02

2. Chronic urticaria: unmet needs, emerging drugs, and new perspectives on personalised treatment;The Lancet;2024-07

3. Evaluating the Toxocara cati extract as a therapeutic agent for allergic airway inflammation;Immunity, Inflammation and Disease;2024-06

4. Effets indésirables des biothérapies de l’asthme sévère;Revue des Maladies Respiratoires;2024-05

5. Long-term safety, durability of response, cessation and switching of biologics;Current Opinion in Pulmonary Medicine;2024-03-01